Recent advances of oncolytic virus in cancer therapy. Issue 10 (2nd October 2020)

• Record Type: Journal Article
• Authors: Mondal, Moumita; Guo, Jingao; He, Ping; Zhou, Dongming
• Is Part Of: Human vaccines & immunotherapeutics. Volume 16:Issue 10(2020)
• Page Start: 2389
• Page End: 2402
• Publication Date: 2020-10-02
• Subjects: Oncolytic viruses -- cancer therapy -- clinical trials; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2020.1723363
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Oncolytic viruses have been taking the front stage in biological therapy for cancer recently. The first and most potent virus to be used in oncolytic virotherapy is human adenovirus. Recently, ongoing extensive research has suggested that other viruses like herpes simplex virus (HSV) and measles virus can also be considered as potential candidates in cancer therapy. An HSV-based oncolytic virus, T-VEC, has completed phase Ш clinical trial and has been approved by the U.S. Food and Drug Administration (FDA) for use in biological cancer therapy. Moreover, the vaccine strain of the measles virus has shown impressive results in pre-clinical and clinical trials. Considering their therapeutic efficacy, safety, and reduced side effects, the use of such engineered viruses in biological cancer therapy has the potential to establish a milestone in cancer research. In this review, we summarize the recent clinical advances in the use of oncolytic viruses in biological therapy for cancer. Additionally, this review evaluates the potential viral candidates for their benefits and shortcomings and sheds light on the future prospects.